10-K: Aptose Biosciences to be Acquired by Hanmi Amid Strong Clinical Data

Aptose Biosciences is set to be acquired by Hanmi Pharmaceutical for C$2.41 per share, providing a definitive path forward for the company despite ongoing financial challenges and promising clinical results for its lead oncology asset, tuspetinib.

Summary

• Aptose Biosciences Inc. has entered into a definitive arrangement agreement with Hanmi Pharmaceutical Co. Ltd. for Hanmi to acquire all outstanding common shares not currently owned by Hanmi Purchasers for C$2.41 per share in cash.
• Shareholders approved the Arrangement on March 31, 2026, and it is expected to close in the first half of 2026, subject to customary closing conditions.
• The company's lead asset, tuspetinib (TUS), a clinical-stage oral kinase inhibitor, is being developed for frontline combination therapy (TUS+VEN+AZA) in newly diagnosed Acute Myeloid Leukemia (AML) patients.
• Clinical data from the Phase 1/2 TUSCANY trial for tuspetinib in newly diagnosed AML patients showed high efficacy and MRD-negative remissions across diverse mutations, with a 100% complete remission rate (CR/CRh) at higher dose levels (80mg and 120mg TUS) and 90% across 40, 80, and 120 mg dose levels.
• Tuspetinib-based therapies demonstrated a favorable safety profile with no dose-limiting toxicities (DLTs), drug-related deaths, QTc prolongation, differentiation syndrome, or CPK elevation reported.
• The company reported a net loss of $25.5 million for the fiscal year ended December 31, 2025, a slight increase from $25.4 million in 2024.
• As of December 31, 2025, Aptose had an accumulated deficit of $566.4 million and a shareholders' deficit of $27.2 million, indicating substantial doubt about its ability to continue as a going concern without additional financing.
• Aptose was delisted from Nasdaq effective April 2, 2025, due to not meeting the stockholders' equity requirement, and its eligibility for continued listing on the Toronto Stock Exchange (TSX) is under review.
• The company completed a 1-for-30 reverse stock split on February 26, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with mixed sentiment. While the clinical data for tuspetinib is highly positive and the Hanmi acquisition provides a clear, albeit low, exit for shareholders, the underlying financial distress and delisting from Nasdaq are significant concerns that are only resolved by the acquisition.

Positives

• Tuspetinib's TUSCANY trial showed high efficacy in newly diagnosed AML patients, with 100% CR/CRh at 80mg and 120mg dose levels and 90% across 40, 80, and 120 mg dose levels.
• The drug demonstrated a favorable safety profile with no dose-limiting toxicities, drug-related deaths, QTc prolongation, differentiation syndrome, or CPK elevation.
• Tuspetinib achieved MRD-negative remissions in 78% of responding subjects, indicating deep and durable responses.
• The drug showed activity across diverse mutational subtypes, including difficult-to-treat TP53/complex karyotype, RAS, and FLT3 wildtype AML, which represents 70% of AML cases.
• The Cohort Safety Review Committee approved dose escalation to 160mg TUS, indicating continued confidence in safety and efficacy.
• The proposed acquisition by Hanmi Pharmaceutical provides a clear exit strategy and a fixed cash value of C$2.41 per share for shareholders.
• The company successfully remediated a previously identified material weakness in internal control over financial reporting related to complex financial instruments.

Negatives

• The company reported a net loss of $25.5 million for the year ended December 31, 2025, and an accumulated deficit of $566.4 million, indicating a history of operating losses.
• Aptose had negative working capital of $2.9 million and a shareholders' deficit of $27.2 million as of December 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern, relying heavily on advances from Hanmi.
• Aptose was delisted from Nasdaq effective April 2, 2025, due to non-compliance with the stockholders' equity requirement.
• The Toronto Stock Exchange is reviewing Aptose's eligibility for continued listing, with a delisting decision deferred until April 17, 2026.
• Two other pipeline molecules, luxeptinib and APTO-253, are not undergoing active clinical development at this time.
• The company's ability to raise additional capital is affected by adverse market conditions, its product pipeline status, and trial delays, making it difficult to secure financing on acceptable terms if the Hanmi Arrangement fails.

Risks

• There is no assurance when or if the Arrangement with Hanmi will be completed, and failure to close could negatively impact the common share price and future business.
• The company may be subject to legal claims, securities class actions, and negative publicity related to the Arrangement, potentially delaying or preventing its consummation.
• The application of interim operating covenants during the Arrangement period may restrict the company's ability to pursue certain business opportunities.
• If the Arrangement is not completed, the company may be required to pay an expense fee of C$300,000 to Hanmi.
• In the event the Arrangement is not completed, the company may be required to implement Alternative CCAA Proceedings, potentially resulting in shareholders receiving no consideration for their shares.
• Certain directors and executive officers may have interests in the Arrangement that differ from general shareholders, including bonuses and indemnification.
• There is substantial doubt about the company's ability to continue as a going concern over the next twelve months without additional financing.
• The company is an early-stage development company with no revenues from product sales and expects to incur net losses for several years.
• Product candidates require significant funding to reach regulatory approval, and securing such funding may be difficult or impossible.
• Clinical trials are long, expensive, and uncertain processes, and product candidates may not receive regulatory approval.
• Delays in clinical testing, including patient enrollment difficulties, could result in delays in commercializing product candidates and harm the business.
• The company relies on contract manufacturers, and quality, cost, or delivery issues could harm business operations.
• The marketplace may not accept the company's products due to intense competition and technological change in the biotechnical and pharmaceutical industries.
• The company may be unable to obtain or maintain patent protection for its technologies, or its products may infringe on the intellectual property rights of others.
• Government funding cuts, such as those potentially affecting the MyeloMATCH program, could adversely impact the business.
• The company is subject to extensive government regulation, and failure to comply could result in fines, penalties, or delays.
• Product liability, clinical trial liability, or environmental liability claims could result in substantial liabilities.
• The company's common share price has been and is likely to continue to be volatile.
• Future sales of common shares by the company or existing shareholders could cause the share price to fall.
• It may be difficult for non-Canadian investors to obtain and enforce judgments against the company due to its Canadian incorporation.

Future Outlook

The Arrangement with Hanmi Pharmaceutical is expected to close in the first half of 2026, subject to customary closing conditions. If completed, Aptose's securities will be delisted from the Toronto Stock Exchange, and shareholders will receive C$2.41 per share. The company expects to devote significant time and resources to the completion of this transaction. Management believes tuspetinib, if approved, could become a preferred kinase inhibitor for frontline AML, second-line AML, maintenance therapy, and hr-MDS, but acknowledges no assurance of approval or significant revenues. The company anticipates continued operating losses and an ongoing need for additional capital if the Arrangement is not completed.

Management Comments

• Management believes that tuspetinib, if approved, could become the preferred kinase inhibitor for inclusion in triplet combination for front line AML patients with wild type FLT3 and with difficult-to-treat patients harboring mutations in the FLT3, RAS or TP53 genes.
• Management believes tuspetinib could also become the preferred kinase inhibitor for inclusion in combination with venetoclax for second line AML patients, serve as an effective agent for maintenance therapy, and for the treatment of third line FLT3 mutated patients.
• Management recognizes that in order to meet capital requirements and to continue operations, additional financing will be necessary.
• Management believes that its tax positions comply with the applicable tax law.

Industry Context

StockSavvy.ai notes that the proposed acquisition of Aptose by Hanmi Pharmaceutical reflects a common trend in the biotechnology sector where smaller, clinical-stage companies with promising assets but significant financial hurdles are acquired by larger pharmaceutical entities. This provides the acquiring company with pipeline expansion and the target company's shareholders with a defined exit. The focus on Acute Myeloid Leukemia (AML) with novel kinase inhibitors like tuspetinib highlights the ongoing unmet medical need in hematologic cancers, particularly for patients ineligible for induction chemotherapy or those with difficult-to-treat mutations. The strong clinical data for tuspetinib, especially its safety profile and efficacy across diverse genetic subgroups, positions it favorably against existing and developing therapies from competitors like AbbVie, Roche, Astellas, and Pfizer, which often face challenges with toxicities or resistance mechanisms. The collaboration with the National Cancer Institute (NCI) through MyeloMATCH trials further validates tuspetinib's potential and aligns with broader industry efforts towards precision medicine in oncology.

Comparison to Industry Standards

• Tuspetinib's 100% CR/CRh response rate at higher dose levels (80mg and 120mg TUS) in newly diagnosed AML patients, exceeding the 66% rate expected from VEN+AZA alone, suggests a superior efficacy profile compared to current standard-of-care doublet therapies.
• The observed 78% MRD negativity rate by central flow cytometry in responding subjects is a high-quality clinical response, often associated with improved long-term outcomes, and compares favorably to reported rates for other AML therapies.
• The favorable safety profile of tuspetinib, with no drug-related QTc prolongations, liver or kidney toxicities, muscle damage, differentiation syndrome, or myelosuppression with continuous dosing, differentiates it from many other kinase inhibitors that often cause significant adverse events.
• Preclinical studies showed tuspetinib had greater inhibitory activity compared to quizartinib on Ba/F3 cells expressing resistance-conferring ITD/TKD double mutations, indicating a potential advantage in overcoming resistance mechanisms that challenge other FLT3 inhibitors.
• In vivo anti-tumor efficacy in MOLM-14 FLT3-ITD/F691L models showed greater tumor growth inhibition for tuspetinib compared to gilteritinib or entospletinib as single agents, and comparable activity to their combination, suggesting a potent single-agent profile against resistant AML.

Corporate Governance

Related Party Transactions

• On November 18, 2025, Aptose entered into a definitive arrangement agreement with Hanmi Pharmaceutical Co. Ltd. and its subsidiary, HS North America Ltd., for the acquisition of all outstanding common shares not owned by Hanmi Purchasers for C$2.41 per share.
• On November 4, 2021, Aptose entered into a licensing agreement with Hanmi for exclusive worldwide rights to tuspetinib, involving an upfront payment of $12.5 million (including $7.5 million in common shares) and potential future milestone payments up to $407.5 million plus tiered royalties.
• Hanmi provided a $10.0 million loan to Aptose on August 27, 2024, with proceeds restricted for tuspetinib-related business operations.
• On March 18, 2025, $1.5 million of Hanmi's indebtedness under the loan agreement was converted into 409,063 common shares of Aptose at $3.70 per share.
• Hanmi provided an uncommitted facility for up to $8.5 million on June 18, 2025, and an additional uncommitted facility for up to $11.9 million on September 22, 2025, to fund tuspetinib development and operations.
• On February 23, 2026, Hanmi provided a Second Amended Facility Agreement for an additional uncommitted facility of up to $11.1 million.
• As of December 31, 2025, Hanmi held 508,710 common shares and 77,972 warrants to purchase common shares of Aptose.
• The company's CEO provided an interest-free short-term advance of $100,000 on June 17, 2025, which was repaid in full on June 26, 2025.

Stakeholder Impact

• Shareholders: Will receive C$2.41 per common share upon completion of the Hanmi acquisition, providing a fixed cash exit. However, they will forgo any future increase in value from the company's long-term plans.
• Employees: The pendency of the Arrangement could cause diversion of management's attention and uncertainty about future roles, potentially affecting retention of key personnel.
• Customers/Patients: The continued development of tuspetinib, especially as a frontline therapy for AML, offers potential new treatment options for patients with life-threatening hematologic cancers.
• Creditors: The company's reliance on Hanmi for financing and the substantial doubt about its going concern status highlight risks for creditors if the Arrangement fails.
• Business Partners: Uncertainty surrounding the Arrangement could lead to delays or deferrals in business decisions by clinical trial partners and other collaborators.

Next Steps

• Completion of the Arrangement with Hanmi Pharmaceutical, expected in the first half of 2026.
• Continued clinical development of tuspetinib, including the ongoing TUSCANY Phase 1/2 study.
• Monitoring of the TSX's continued listing review, with a decision expected by April 17, 2026.
• Leasing of new office space in San Diego, California, with commencement expected in June 2026.
• Potential further advances from Hanmi under the Second Amended Facility Agreement (up to $11.1 million, with $4.0 million already received as of March 27, 2026).

Key Dates

Recommendation

The recommendation is 'hold' for existing shareholders due to the pending acquisition by Hanmi Pharmaceutical at a fixed cash price of C$2.41 per share. With shareholder approval already secured and the transaction expected to close in the first half of 2026, the upside potential for the common shares is capped at the acquisition price. For new investors, there is no significant investment opportunity in the common shares at this stage, as the value is largely determined by the acquisition terms. The acquisition provides a certain exit for existing shareholders, mitigating the significant going concern risks and Nasdaq delisting issues highlighted in the filing.

Keywords

Aptose Biosciences, Hanmi Pharmaceutical, Acquisition, Tuspetinib, AML, Acute Myeloid Leukemia, Oncology, Clinical Trials, Phase 1/2 TUSCANY, Biotechnology, SEC Filing, 10-K, Corporate Arrangement, MRD-negative, Complete Remission, Kinase Inhibitor, Going Concern, Nasdaq Delisting, TSX Listing Review